Dear Editor, Atopic dermatitis (AD) and alopecia areata (AA) are two common diseases that
can coexist in the same patient, sharing some pathogenetic aspects such as the …

This case report describes the first successful treatment of alopecia areata and atopic
dermatitis with the Janus kinase 1 inhibitor upadacitinib in a paediatric patient. After minimal …

Dear Editor, Upadacitinib is an oral Janus kinase (JAK)-1 inhibitor approved by the
European Medicine Agency for the management of moderate to severe atopic dermatitis …

A significant reduction of mean baseline severity of alopecia tool (SALT) score (95.1 6 9.6)
was detected as early as after 4 weeks of treatment (77.6 6 28.2, P ¼. 0087), with …

Discussion We report a temporal relationship between dupilumab and the subsequent
development of AA. Of course, temporal cannot be interpreted as causal; however, we …

DISCUSSION Our case showed significant improvement of AA during dupilumab treatment
for AD. To date, Darrigade et al. reported a similar case (1), and Penzi et al.(2) reported a …

DEAR EDITOR, Alopecia areata (AA) is one of the most common autoimmune diseases;
however, the pathogenesis of the condition has yet to be fully elucidated. A recent study …

We report phenotypic switching from atopic dermatitis to psoriasis in a 44‐year‐old man
during treatment with upadacitinib. The patient also had experienced a similar course with …

Atopic dermatitis (Ad) is a widespread inflammatory skin condition affecting individuals of all
age groups. recent research has identified Ad in older patients as a distinct clinical entity (1) …

Abstract Dear Editor While dupilumab has emerged as an effective treatment for moderate-to-
severe atopic dermatitis (AD) since its approval, interleukin (IL)-4 and 13 blockade has also …